Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;46(4):216-221.
doi: 10.1111/jorc.12324. Epub 2020 Mar 27.

Use of the esa resistance index to guide dosing for anaemia management

Edward A Ross  1 , Jennifer L Paugh-Miller  2 , Xuerong Wen  3 , Robert W Nappo  4
Affiliations

Use of the esa resistance index to guide dosing for anaemia management

Edward A Ross et al. J Ren Care. 2020 Dec.

Abstract

Background: Identifying erythropoiesis-stimulating agent (ESA) resistance is important for treating reversible causes, reaching target haemoglobin levels with minimal dosing, avoiding adverse effects and reducing costs. The resistance index (RI, dose/kg weight/g haemoglobin/dl) is reportedly superior to absolute or weight-based dosing.

Objectives: With the growing number of ESA classes and medications, our goal was to develop methodology to establish RI ranges in otherwise healthy haemodialysis patients as a structured approach to identify remediable causes of anaemia.

Design: We retrospectively studied anaemia management with darbepoetin in 100 chronic haemodialysis patients and a subgroup of 48 without identifiable conditions that impair erythropoiesis. Data included inflammatory and bone marrow conditions, medications with hematologic effects, catheter use, iron, parathyroid and dialysis measures.

Results: The haematologically healthy group was aged 57.1 ± 1.9 SEM years, 33% diabetic, with haemoglobin 10.4 ± 0.2 g/dl. The darbepoetin RI (DRI) values were 0.05 ± 0.01, absolute dose 38.5 ± 3.5 mcg/week and weight-based 0.50 ± 0.05 mcg/kg. Regression analyses included iron saturation, ferritin, parathyroid hormone and urea reduction ratio. DRI was superior to other dosing approaches based on the distribution of results (kurtosis) and discordance between the measures that occurred in 17% of patients at haemoglobin target.

Conclusions: We demonstrate the value of determining the RI for use with expanding ESA choices, using as an example how DRI values can be established for healthy haemodialysis patients so as to guide dosing. When elevated, the RI can trigger evaluation for remediable factors causing hyporesponsiveness even when haemoglobin goals have been reached.

Keywords: Anaemia; Biosimilars; Darbepoetin; Erythropoiesis resistance; Erythropoiesis resistance index.

PubMed Disclaimer

References

REFERENCES

    1. Badve S.V., Beller E.M., Cass A. et al. (2013). Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database of Systematic Reviews, 8, CD006861.
    1. Bommer J., Asmus G., Wenning M. et al. (2008). A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrology, Dialysis, Transplantation, 23(12), 4002-4008.
    1. Chung S., Song H.C., Shin S.J. et al. (2012). Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodialysis International, 16(2), 181-187.
    1. Fishbane S., Kowalski E.A., Imbriano L.J. et al. (1996). The evaluation of iron status in hemodialysis patients. Journal of the American Society of Nephrology, 7(12), 2654-2657.
    1. Johnson D.W., Pascoe E.M., Badve S.V. et al. (2014). A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. American Journal of Kidney Diseases, 65, 49-57.

LinkOut - more resources